Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMMJ1IS)

Drug Name
Prolixin decanoate Drug Info
Synonyms
Modecate; Dapotum D; Flufenazine decanoate; Fluorophenazine decanoate; Fluphenaline decanoate; Fluphenazine decanoate; Fluphenazine depot; Moditen depot; Fluphenazine O-decanoate; Moditen-depo; Prolixin decanoate (TN); SQ 10,733; Fluphenazine decanoate (JAN/USP); Decanoic acid, 2-[4-[3-[2-(trifluoromethyl)phenothiazin-10-yl]propyl]-1-piperazinyl]ethyl ester; Decanoic acid, 2-[4-[3-[2-(trifluoromethyl)-10H-phenothiazin-10-yl]propyl]-1-piperazinyl]ethyl ester; Decanoic acid, 2-(4-(3-(2-(trifluoromethyl)phenothiazin-10-yl)propyl)-1-piperazinyl)ethyl ester; Decanoic acid, 2-(4-(3-(2-(trifluoromethyl)-10H-phenothiazin-10-yl)propyl)-1-piperazinyl)ethyl ester; 2-(4-(3-(2-(Trifluoromethyl)phenothiazin-10-yl)propyl)-1-piperazinyl)ethyl decanoate; 2-(4-{3-[2-(trifluoromethyl)-10H-phenothiazin-10-yl]propyl}piperazin-1-yl)ethyl decanoate; 2-[4-[3-[2-(trifluoromethyl)phenothiazin-10-yl]propyl]piperazin-1-yl]ethyl decanoate
Indication
Disease Entry ICD 11 Status REF
Schizophrenia 6A20 Approved [1]
Therapeutic Class
Antipsychotic Agents
Cross-matching ID
PubChem CID
3388
ChEBI ID
CHEBI:5124
CAS Number
CAS 5002-47-1
TTD Drug ID
DMMJ1IS
INTEDE Drug ID
DR0722

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
DME
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Discontinued Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting 5-HT 1B receptor (HTR1B)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Metergolin DMJFP6G Hyperprolactinaemia 5A60.1 Approved [4]
Eletriptan DMW649X Migraine 8A80 Approved [2]
Zolmitriptan DM1IB4Q Migraine 8A80 Approved [2]
Frovatriptan DM7RE8P Migraine 8A80 Approved [2]
Fluphenazine DMIT8LX Psychotic disorder 6A20-6A25 Approved [2]
Naratriptan DMO50U2 Headache 8A80-8A84 Approved [5]
Eltoprazine DMW6C81 Attention deficit hyperactivity disorder 6A05.Z Phase 3 [6]
NXN-188 DMMBAIH Migraine 8A80 Phase 2 [7]
[N-methyl-3H(3)]AZ-10419369 DMSCV02 Mood disorder 6A60-6E23 Phase 1 [8]
Alniditan DMFE3CT Migraine 8A80 Discontinued in Phase 3 [9]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Metabolized By Cytochrome P450 2D6 (CYP2D6)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Doxorubicin DMVP5YE Acute myelogenous leukaemia 2A41 Approved [10]
Progesterone DMUY35B Amenorrhea GA20.0 Approved [11]
Tamoxifen DMLB0EZ Breast cancer 2C60-2C65 Approved [12]
Acetaminophen DMUIE76 Allergic rhinitis CA08.0 Approved [13]
Imatinib DM7RJXL Acute lymphoblastic leukaemia 2A85 Approved [14]
Quinine DMSWYF5 Malaria 1F40-1F45 Approved [15]
Propofol DMB4OLE Anaesthesia 9A78.6 Approved [16]
Dopamine DMPGUCF Acromegaly 5A60.0 Approved [17]
Nicotine DMWX5CO Lung cancer 2C25.0 Approved [18]
Propranolol DM79NTF Angina pectoris BA40 Approved [19]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
5-HT 1B receptor (HTR1B) TTK8CXU 5HT1B_HUMAN Modulator [2]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 2D6 (CYP2D6) Main DME DECB0K3 CP2D6_HUMAN Substrate [3]

References

1 FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (NDA) 016727.
2 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
3 Effect of antipsychotic drugs on human liver cytochrome P-450 (CYP) isoforms in vitro: preferential inhibition of CYP2D6. Drug Metab Dispos. 1999 Sep;27(9):1078-84.
4 Two amino acid differences in the sixth transmembrane domain are partially responsible for the pharmacological differences between the 5-HT1D beta and 5-HT1E 5-hydroxytryptamine receptors. J Neurochem. 1996 Nov;67(5):2096-103.
5 Triptans in pregnancy. Ther Drug Monit. 2008 Feb;30(1):5-9.
6 Clinical pipeline report, company report or official report of Jazz Pharmaceuticals.
7 Company report (NeurAxon)
8 5-HT1B and other related serotonergic proteins are altered in APPswe mutation. Neurosci Lett. 2015 May 6;594:137-43.
9 Agonistic properties of alniditan, sumatriptan and dihydroergotamine on human 5-HT1B and 5-HT1D receptors expressed in various mammalian cell lines. Br J Pharmacol. 1998 Apr;123(8):1655-65.
10 Inhibitory effects of anticancer drugs on dextromethorphan-O-demethylase activity in human liver microsomes. Cancer Chemother Pharmacol. 1993;32(6):491-5.
11 Effect of genetic polymorphism on the metabolism of endogenous neuroactive substances, progesterone and p-tyramine, catalyzed by CYP2D6. Brain Res Mol Brain Res. 2004 Oct 22;129(1-2):117-23.
12 CYP2D6 polymorphisms and tamoxifen metabolism: clinical relevance. Curr Oncol Rep. 2010 Jan;12(1):7-15.
13 Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
14 Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
15 Inhibition of cytochrome P450 2D6: structure-activity studies using a series of quinidine and quinine analogues. Chem Res Toxicol. 2003 Apr;16(4):450-9.
16 Effects of propofol on human hepatic microsomal cytochrome P450 activities. Xenobiotica. 1998 Sep;28(9):845-53.
17 Pharmacogenetics of schizophrenia. Am J Med Genet. 2000 Spring;97(1):98-106.
18 Roles of CYP2A6 and CYP2B6 in nicotine C-oxidation by human liver microsomes. Arch Toxicol. 1999 Mar;73(2):65-70.
19 Structure-activity relationship for human cytochrome P450 substrates and inhibitors. Drug Metab Rev. 2002 Feb-May;34(1-2):69-82.